Want a full personalised taper protocol?
This page shows a quick schedule for this drug. For the guided path — pre-taper risk quiz, formulation-aware steps, and email delivery — start from the main calculator.
Paxil / Seroxat (Paroxetine) Tapering Guide
Paxil (paroxetine) is an SSRI antidepressant, sold as Paxil in the US and Seroxat in the UK. It is used for depression and several anxiety disorders. This guide and medication taper calculator help you plan how to wean off Paxil safely with your prescriber.
Dosage
Paroxetine tablets commonly come in 10 mg, 20 mg, and 30 mg strengths (many are scored). A licensed oral suspension (about 2 mg/mL — Paxil suspension in the US; Rosemont liquid in the UK) supports small final steps that tablets cannot.
Paroxetine has a short half-life and the highest SSRI withdrawal-severity ranking in many studies, so slow hyperbolic tapering with an early switch to liquid is standard practice.
Paroxetine taper schedule
Choose a common starting dose to preview the full hyperbolic schedule — free, no email required. This schedule has 42 steps and takes about 164 weeks in total; your prescriber may adjust the pace based on how you feel.
Starting dose
- Selected start
- 20 mg/day · 1× daily
- Taper speed
- Slow
- Region (formulations)
- US
- Tablet/liquid products used for dosing tips — not your location. Example uses US formulary; change region in the custom builder.
- Modelled occupancy at start
- ~70.8%
Swipe sideways to see every column.
| Step | Daily (mg) | How to take it | Per dose × 1/day | Hold (weeks) |
|---|---|---|---|---|
| 0 | 20 | Your current dose — hold steady before step 1. | 20 mg × 1 | — |
| 1 | 17.7 | Measure 8.85 mL of 2 mg/mL Paxil suspension (≈ 17.7 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 17.7 mg × 1 | 4 |
| 2 | 15.8 | Measure 7.9 mL of 2 mg/mL Paxil suspension (≈ 15.8 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 15.8 mg × 1 | 4 |
| 3 | 14.2 | Measure 7.1 mL of 2 mg/mL Paxil suspension (≈ 14.2 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 14.2 mg × 1 | 4 |
| 4 | 12.85 | Measure 6.425 mL of 2 mg/mL Paxil suspension (≈ 12.85 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 12.85 mg × 1 | 4 |
| 5 | 10 | Take 1 × 10 mg Paxil tablet (10 mg active ingredient total). | 10 mg × 1 | 4 |
| 6 | 9.2 | Measure 4.6 mL of 2 mg/mL Paxil suspension (≈ 9.2 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 9.2 mg × 1 | 4 |
| 7 | 8.45 | Measure 4.225 mL of 2 mg/mL Paxil suspension (≈ 8.45 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 8.45 mg × 1 | 4 |
| 8 | 7.8 | Measure 3.9 mL of 2 mg/mL Paxil suspension (≈ 7.8 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 7.8 mg × 1 | 4 |
| 9 | 7.2 | Measure 3.6 mL of 2 mg/mL Paxil suspension (≈ 7.2 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 7.2 mg × 1 | 4 |
| 10 | 6.65 | Measure 3.325 mL of 2 mg/mL Paxil suspension (≈ 6.65 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 6.65 mg × 1 | 4 |
| 11 | 6.15 | Measure 3.075 mL of 2 mg/mL Paxil suspension (≈ 6.15 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 6.15 mg × 1 | 4 |
| 12 | 5.7 | Measure 2.85 mL of 2 mg/mL Paxil suspension (≈ 5.7 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 5.7 mg × 1 | 4 |
| 13 | 5.3 | Measure 2.65 mL of 2 mg/mL Paxil suspension (≈ 5.3 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 5.3 mg × 1 | 4 |
| 14 | 4.95 | Take half of a scored 10 mg tablet (5 mg) ≈ 5 mg active ingredient. | 4.95 mg × 1 | 4 |
| 15 | 4.6 | Measure 2.3 mL of 2 mg/mL Paxil suspension (≈ 4.6 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 4.6 mg × 1 | 4 |
| 16 | 4.3 | Measure 2.15 mL of 2 mg/mL Paxil suspension (≈ 4.3 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 4.3 mg × 1 | 4 |
| 17 | 4 | Measure 2 mL of 2 mg/mL Paxil suspension (≈ 4 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 4 mg × 1 | 4 |
| 18 | 3.75 | Measure 1.875 mL of 2 mg/mL Paxil suspension (≈ 3.75 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 3.75 mg × 1 | 4 |
| 19 | 3.5 | Measure 1.75 mL of 2 mg/mL Paxil suspension (≈ 3.5 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 3.5 mg × 1 | 4 |
| 20 | 3.25 | Measure 1.625 mL of 2 mg/mL Paxil suspension (≈ 3.25 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 3.25 mg × 1 | 4 |
| 21 | 3.05 | Measure 1.525 mL of 2 mg/mL Paxil suspension (≈ 3.05 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 3.05 mg × 1 | 4 |
| 22 | 2.85 | Measure 1.425 mL of 2 mg/mL Paxil suspension (≈ 2.85 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 2.85 mg × 1 | 4 |
| 23 | 2.65 | Measure 1.325 mL of 2 mg/mL Paxil suspension (≈ 2.65 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 2.65 mg × 1 | 4 |
| 24 | 2.45 | Measure 1.225 mL of 2 mg/mL Paxil suspension (≈ 2.45 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 2.45 mg × 1 | 4 |
| 25 | 2.25 | Measure 1.125 mL of 2 mg/mL Paxil suspension (≈ 2.25 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 2.25 mg × 1 | 4 |
| 26 | 2.1 | Measure 1.05 mL of 2 mg/mL Paxil suspension (≈ 2.1 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 2.1 mg × 1 | 4 |
| 27 | 1.95 | Measure 0.975 mL of 2 mg/mL Paxil suspension (≈ 1.95 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 1.95 mg × 1 | 4 |
| 28 | 1.8 | Measure 0.9 mL of 2 mg/mL Paxil suspension (≈ 1.8 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 1.8 mg × 1 | 4 |
| 29 | 1.65 | Measure 0.825 mL of 2 mg/mL Paxil suspension (≈ 1.65 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 1.65 mg × 1 | 4 |
| 30 | 1.5 | Measure 0.75 mL of 2 mg/mL Paxil suspension (≈ 1.5 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 1.5 mg × 1 | 4 |
| 31 | 1.35 | Measure 0.675 mL of 2 mg/mL Paxil suspension (≈ 1.35 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 1.35 mg × 1 | 4 |
| 32 | 1.25 | Measure 0.625 mL of 2 mg/mL Paxil suspension (≈ 1.25 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 1.25 mg × 1 | 4 |
| 33 | 1.15 | Measure 0.575 mL of 2 mg/mL Paxil suspension (≈ 1.15 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 1.15 mg × 1 | 4 |
| 34 | 1.05 | Measure 0.525 mL of 2 mg/mL Paxil suspension (≈ 1.05 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 1.05 mg × 1 | 4 |
| 35 | 0.95 | Measure 0.475 mL of 2 mg/mL Paxil suspension (≈ 0.95 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 0.95 mg × 1 | 4 |
| 36 | 0.85 | Measure 0.425 mL of 2 mg/mL Paxil suspension (≈ 0.85 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 0.85 mg × 1 | 4 |
| 37 | 0.75 | Measure 0.375 mL of 2 mg/mL Paxil suspension (≈ 0.75 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 0.75 mg × 1 | 4 |
| 38 | 0.65 | Measure 0.325 mL of 2 mg/mL Paxil suspension (≈ 0.65 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 0.65 mg × 1 | 4 |
| 39 | 0.55 | Measure 0.275 mL of 2 mg/mL Paxil suspension (≈ 0.55 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 0.55 mg × 1 | 4 |
| 40 | 0.45 | Measure 0.225 mL of 2 mg/mL Paxil suspension (≈ 0.45 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 0.45 mg × 1 | 4 |
| 41 | 0.4 | Measure 0.2 mL of 2 mg/mL Paxil suspension (≈ 0.4 mg active ingredient). Use an oral syringe; confirm concentration on the bottle. | 0.4 mg × 1 | 4 |
Rows highlighted: larger occupancy drop than target — consider smaller steps or longer holds. If symptoms are intolerable, return to the previous dose and talk to your prescriber.
Want a copy to keep?
The full paroxetine schedule is already shown below. Enter your email to also receive a PDF and HTML copy you can save or share with your prescriber — optional, and we never gate the schedule behind it.
It's not a substitute for medical advice. This calculator can help you visualise a tapering schedule but before making any changes to your medication plan it's necessary to consult a medical professional. Ask a psychiatrist — available after you request your protocol.
Dose vs occupancy
This taper is spread across 42 gradual steps. The curve below shows why the last few milligrams matter most: at low doses, small dose changes produce large drops in serotonin-transporter occupancy.
What this shows: the non-linear relationship between dose and serotonin transporter (SERT) occupancy. The curve is flat at high doses — most transporters are already blocked, so a dose cut has little biological impact — and much steeper at low doses, where even a 1–2 mg reduction causes a disproportionately large drop in occupancy. Your taper steps are spaced along this curve so each step removes a similar amount of occupancy.
Hill curve of modelled receptor occupancy versus dose. Current dose near 20.0 milligrams per day.
Modelled Hill-curve occupancy — illustrative only. PET-derived parameters vary by study; your prescriber may use different clinical targets. Small mg changes near zero can still produce large occupancy shifts.
How to Taper Off Paxil / Seroxat (Paroxetine) Safely
How to taper off Paxil (paroxetine; Seroxat in the UK) safely requires extra caution: it has a relatively short half-life (~21 hours), no active metabolite to cushion the fall, and a steep occupancy curve at low doses. Coming off paroxetine is often the hardest SSRI taper, so a slow hyperbolic taper schedule — with liquid for the final milligrams — should be planned with your prescriber.
People searching how to wean off Paxil or get off antidepressants after anxiety treatment frequently report intense dizziness and brain zaps after fast cuts. Occupancy-based deprescribing is the approach supported by Horowitz & Taylor (2019), the Maudsley Deprescribing Guidelines (2024), and NICE NG222.
What coming off Paxil actually feels like, week by week
After an oversized cut, paroxetine withdrawal often starts within one to three days: severe dizziness, brain zaps, nausea, agitation, insomnia, crying spells, and sensory disturbances. Some people feel flu-like and emotionally raw at once.
In a careful taper each step should still be noticeable for some, but settle within one to two weeks. The last 10 mg of a Paxil taper schedule usually takes as long as everything above it.
“Miss Seroxat by half a day and the dizziness starts. Going from 10 mg down was the part that floored me — I had to switch to the liquid to get anywhere.”
“People kept telling me 10 mg is a low dose, just stop. For me the side effects of coming off Paxil were worst right at the bottom.”
Withdrawal or relapse — how to tell them apart
Paroxetine withdrawal is early, physical/sensory, and rapidly eased by reinstatement. Relapse of anxiety or depression appears later, lacks the zap signature, and does not clear within a day of putting the dose back (Cosci & Chouinard, 2020).
Paxil taper schedules by starting dose (30, 20, 10 mg)
Paroxetine comes as 10, 20, and 30 mg tablets plus a 2 mg/mL oral suspension (Paxil suspension / Rosemont). “Cut by 10 mg” advice is far too coarse. Notes below are high → low.
From 30 mg: upper steps (30 → 25 → 20) are usually more tolerable while occupancy is flatter. How to taper off Paxil 30 mg is mainly about pacing yourself for the harder lower range.
From 20 mg: a Paxil taper schedule from 20 mg should shrink steps (for example toward 15 → 10) rather than jumping straight to 10 mg and stopping.
From 10 mg: how to taper off Paxil 10 mg means planning 7, 5, 3, 2, 1 mg with the suspension — a tablet-splitter cannot reach these accurately.
If it gets worse: pausing and reinstatement
Hold, partially reinstate, or seek advice if a step is intolerable. Paroxetine's kinetics mean relief after reinstatement is often noticeable within a day.
Resume with smaller steps and longer holds. For people who cannot get past the bottom, some clinicians discuss a fluoxetine bridge — that is a specialist decision, not a DIY switch.
Suspension and small doses of paroxetine
The licensed oral suspension is the practical tool for coming off Paxil below 10 mg. Measure with an oral syringe; ask pharmacy to confirm concentration and technique.
Compounded liquids are an alternative where suspension is unavailable. Keep the last milligrams as even occupancy steps.
The bottom line
Paxil is the toughest common SSRI to stop, but it is doable with a slow hyperbolic plan, early access to liquid, and willingness to pause. Respect the short half-life and the steep curve under 10 mg when you wean off paroxetine.
Key facts about hyperbolic antidepressant tapering
The calculator algorithm is based on peer-reviewed research and has been reviewed by our medical advisors to ensure the accuracy of the tapering model.
72%
discontinued their antidepressant using hyperbolic tapering strips in a real-world study
71% of the same people had previously tried to stop at least once and been unsuccessful; the study did not record which method those earlier attempts used. Figures come from tapering-strip research and may not generalise to every taper.
Source: Groot et al., Therapeutic Advances in Psychopharmacology 2021
56 days
median taper length in that tapering-strip study — not a target; many people taper over 6–12 months or longer
This median reflects tapering-strip use in one study. Your timeline depends on how long you have taken the medication, your withdrawal symptoms, and previous attempts — slower is often safer.
Source: Groot et al., Therapeutic Advances in Psychopharmacology 2021
10%
serotonin transporter occupancy per tapering step
This linear reduction prevents withdrawal. Slower, more gradual tapering over several months has shown greater success in reducing withdrawal symptoms than short tapers.
Claro — tapering companion
A protocol isn’t enough — you need support.
Tapering can take months, sometimes years. Claro helps you track each step, log symptoms, and spot when a reduction was too fast — with psychiatrist-reviewed guidance. Join early access while we launch the app.
Frequently asked questions about paroxetine
Common questions about how to taper off paroxetine, hyperbolic schedules, and withdrawal — written for people who want to come off antidepressants safely with their prescriber.
How do you taper off Paxil (paroxetine)?
Why is Paxil one of the hardest antidepressants to taper?
What is an antidepressant tapering calculator?
Why use a tapering calculator?
How does an antidepressant taper calculator work?
What is hyperbolic tapering and why is it recommended?
What is the safest way to taper off antidepressants?
How slowly should antidepressants be reduced?
What are common antidepressant withdrawal symptoms?
What is the difference between antidepressant withdrawal and relapse?
Is it dangerous to stop antidepressants cold turkey?
Why are the last antidepressant dose reductions often the hardest?
Which antidepressants are hardest to taper off?
Need a different dose or speed?
Use the guided builder to enter your current dose, region, and taper preset — then email your personalised protocol.
Request custom protocol →Clinical references
- [1]Horowitz MA, Taylor D. Tapering of SSRI treatment to mitigate withdrawal symptoms. The Lancet Psychiatry 2019.doi:10.1016/S2215-0366(19)30032-XProposes hyperbolic dose reduction based on receptor-occupancy curves; the methodological basis of every modern taper calculator.
- [2]Horowitz MA, Taylor D. The Maudsley Deprescribing Guidelines. Wiley 2024.doi:10.1002/9781394291052Per-drug operational manual for hyperbolic tapering across SSRIs, SNRIs, benzodiazepines, gabapentinoids, and antipsychotics.
- [3]Davies J, Read J. A systematic review into the incidence, severity and duration of antidepressant withdrawal effects. Addictive Behaviors 2019.doi:10.1016/j.addbeh.2018.08.027Systematic review: 56% of people who discontinue antidepressants experience withdrawal effects; 46% rate them as severe.
- [4]Henssler J et al. Incidence of antidepressant discontinuation symptoms: a systematic review and meta-analysis. The Lancet Psychiatry 2024.doi:10.1016/S2215-0366(24)00133-0Meta-analysis of 79 studies (≈21,000 patients): pooled incidence of discontinuation symptoms ~31%; severe symptoms ~2.8%.
- [5]Groot PC, van Os J. Successful use of tapering strips for hyperbolic reduction of antidepressant dose: a cohort study. Therapeutic Advances in Psychopharmacology 2021.doi:10.1177/2045125321103932772% of patients successfully discontinued antidepressants after switching to the hyperbolic model; 71% had previously failed to come off without tapering strips.
- [6]Groot PC, van Os J. Antidepressant tapering strips to help people come off medication: real-world outcomes. Therapeutic Advances in Psychopharmacology 2023.doi:10.1177/20451253231171518Of 1,194 patients using hyperbolic taper strips after previous failed attempts, ~71% successfully discontinued their antidepressant.
- [7]Framer A. What I have learnt from helping thousands of people taper off antidepressants and other psychotropic medications. Therapeutic Advances in Psychopharmacology 2021.doi:10.1177/2045125321991274Describes the "windows and waves" pattern of withdrawal recovery and supports patient-led pacing.
- [8]Hengartner MP et al. Protracted withdrawal syndrome after stopping antidepressants: a descriptive quantitative analysis of consumer narratives. Therapeutic Advances in Psychopharmacology 2020.doi:10.1177/2045125320967183Descriptive analysis of 69 protracted withdrawal cases: median duration 79 weeks; 47% report suicidality during withdrawal.
- [9]Cosci F, Chouinard G. Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychotherapy and Psychosomatics 2020.doi:10.1159/000506868Taxonomy distinguishing new withdrawal symptoms, rebound, and persistent post-withdrawal disorder; the standard framework for withdrawal vs. relapse.
- [10]Kalfas M et al. Incidence and Nature of Antidepressant Discontinuation Symptoms. JAMA Psychiatry 2025.doi:10.1001/jamapsychiatry.2025.1362Recent meta-analysis: dizziness was the most common discontinuation symptom in the first 2 weeks after stopping antidepressants, followed by nausea, vertigo, and nervousness.
- [11]Gabriel M, Sharma V. Antidepressant discontinuation syndrome. Canadian Medical Association Journal 2017.doi:10.1503/cmaj.160991Clinical review of antidepressant discontinuation syndrome: onset within days of dose reduction, typical symptom course, and management.
- [12]Papp A, Onton J. Brain Zaps: An Underappreciated Symptom of Antidepressant Discontinuation. The Primary Care Companion for CNS Disorders 2018.doi:10.4088/pcc.18m02311Characterises "brain zaps" — brief electric-shock sensations — as a common antidepressant discontinuation symptom.
- [13]Wang J, Cosci F. Acute and persistent withdrawal syndromes following discontinuation of antidepressants in children and adolescents: a systematic review. Therapeutic Advances in Psychopharmacology 2025.doi:10.1177/20451253251404780Systematic review of acute and persistent antidepressant withdrawal syndromes; reinforces reducing only when stable and under supervision.
- [14]Horowitz M, Taylor D. Distinguishing relapse from antidepressant withdrawal: clinical practice and antidepressant discontinuation studies. BJPsych Advances 2022.doi:10.1192/bja.2021.62Frames how clinicians can distinguish antidepressant withdrawal from relapse of the underlying condition.
- [15]Sørensen A, Ruhé HG, Munkholm K. The relationship between dose and serotonin transporter occupancy of antidepressants — a systematic review. Molecular Psychiatry 2021.doi:10.1038/s41380-021-01285-wSystematic review of dose–SERT-occupancy relationships across antidepressants; confirms the hyperbolic curve underlying proportional tapering.
- [16]Reeve R, Turner JR. Pharmacodynamic models: parameterizing the Hill equation, Michaelis-Menten, the logistic curve, and relationships among these models. Journal of Biopharmaceutical Statistics 2013.doi:10.1080/10543406.2012.756496Explains how the Hill equation, Michaelis-Menten, and logistic models relate — the mathematical basis for the occupancy curve used here.
- [17]Preskorn SH. The use of biomarkers in psychiatric research: how serotonin transporter occupancy explains the dose-response curves of SSRIs. Journal of Psychiatric Practice 2012.LinkShows how SERT occupancy explains the non-linear dose–response curves of SSRIs.
- [18]Cohrs D, Shapiro B. The relationship between SERT occupancy and extracellular serotonin concentration is hyperbolic, not linear: implications for safely tapering SRI antidepressants. SSRN (preprint) 2026.doi:10.2139/ssrn.6176553Argues the SERT-occupancy to serotonin relationship is itself hyperbolic, reinforcing proportional (hyperbolic) tapering.
- [19]Moncrieff J et al. Evidence on antidepressant withdrawal: an appraisal and reanalysis of a recent systematic review. Psychological Medicine 2025.doi:10.1017/S0033291725100652Reappraisal of recent withdrawal-incidence evidence; relevant to how withdrawal rates are interpreted.
- [20]Wilson E, Lader M. A review of the management of antidepressant discontinuation symptoms. Therapeutic Advances in Psychopharmacology 2015.doi:10.1177/2045125315612334Practical review of how to manage antidepressant discontinuation symptoms, including tapering and reinstatement.
- [21]Groot PC, van Os J. Outcome of antidepressant drug discontinuation with tapering strips after 1–5 years. Therapeutic Advances in Psychopharmacology 2020.doi:10.1177/2045125320954609Long-term follow-up (1–5 years) of patients who discontinued antidepressants using hyperbolic taper strips.
- [22]Gury C, Cousin F. Pharmacokinetics of SSRI antidepressants: half-life and clinical applicability. L'Encéphale 1999.LinkHalf-life data for SSRIs — explains why short-half-life drugs (paroxetine, venlafaxine) provoke faster withdrawal.
- [23]Mayo Clinic. Antidepressant withdrawal: Is there such a thing?. Mayo Clinic — Expert Answers 2024.LinkPatient-facing explainer on antidepressant discontinuation symptoms and gradual tapering.
- [24]NHS Scotland — Right Decision Service. Antidepressants — quality prescribing: difficulty withdrawing from an SSRI/SNRI. NHS Scotland 2024.LinkNHS Scotland guidance on recognising and managing difficulty withdrawing from SSRIs/SNRIs.
- [25]The Carlat Psychiatry Report. Clinical pearls for hyperbolic tapering of psychiatric medications in older adults. The Carlat Report 2024.LinkPractical clinical pearls for applying hyperbolic tapering, including in older adults.
- [26]Royal College of Psychiatrists. Stopping antidepressants — information for patients and carers. Royal College of Psychiatrists 2024.LinkRCPsych patient-facing guidance on coming off antidepressants safely.
- [27]Meyer JH et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses. American Journal of Psychiatry 2004.doi:10.1176/appi.ajp.161.5.826PET-imaged SERT occupancy data for citalopram, sertraline, paroxetine, fluoxetine, and venlafaxine — the empirical basis for the hyperbolic curves in this calculator.
- [28]National Institute for Health and Care Excellence (NICE). Depression in adults: treatment and management. NICE guideline [NG222]. NICE 2022.LinkUK national guideline endorsing proportional (hyperbolic) tapering and the use of liquid formulations to enable small final doses.
- [29]Royal College of Psychiatrists. Stopping antidepressants — position statement (CR225). Royal College of Psychiatrists 2020.LinkRCPsych acknowledges withdrawal can be severe and long-lasting; recommends slow, individualised tapers.
- [30]NHG et al. Multidisciplinary document: Discontinuation of SSRIs and SNRIs (2018; revised 2023). Multidisciplinary Document (Netherlands) 2018.LinkFirst national guideline to explicitly endorse hyperbolic tapering and the use of taper strips (compounded by Regenboog Apotheek).
- [31]Medicines and Healthcare products Regulatory Agency (MHRA). Summary of Product Characteristics — SSRI and SNRI products (UK). electronic Medicines Compendium (emc) 2023.LinkAuthoritative UK formulary data (tablet strengths, oral solutions) used to validate the UK region in the calculator.
- [32]U.S. Food and Drug Administration. Prescribing information (Structured Product Labeling) for SSRI/SNRI products. FDA / DailyMed 2024.LinkAuthoritative US formulary data (tablet strengths, oral solutions/concentrates) used to validate the US region in the calculator.
- [33]Health Canada. Health Canada — Drug Product Database. Health Canada 2024.LinkAuthoritative Canadian formulary data used to validate the Canada region in the calculator.
- [34]Therapeutic Goods Administration (TGA). Therapeutic Goods Administration — Australian Register of Therapeutic Goods (ARTG). TGA / ARTG 2024.LinkAuthoritative Australian formulary data used to validate the Australia region in the calculator.
- [35]College ter Beoordeling van Geneesmiddelen (CBG-MEB). CBG-MEB — Medicines Information Bank (Netherlands). CBG-MEB 2024.LinkAuthoritative Dutch formulary data; cross-checked with Regenboog Apotheek taper-strip availability.
- [36]Regenboog Apotheek, Cinetto. Taperingstrip.com — Regenboog Apotheek. Patient resource (NL) 2024.LinkPioneer of standardised taper strips referenced in the Dutch national guideline.
If you are in crisis or having thoughts of suicide, do not wait for an email response. Find a crisis helpline near you immediately →